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A series of 8 peptides derived from the amino acid sequence accommodating the plasmin cleavage site in vitron~tin were synthesized and used 
to map Its binding site for the type 1 plasminogen activator inhtbitor (PAl-I). This mapping assigned the inhibitor binding s&e to the K”““-R’70 
region with high affinity recognition elements within the K”“*-R”” sequence. These results account for our previous finding that cleavage of the 
R’“‘--5”6’ bond by plasmin signifi~ntly reduces the affinity between PAI-I and vitronectin, since it splits the PAI-I binding site in two. Furthermore, 
in the case of the two-cham form of vitronectln, this cleavage detaches the S”6’--R’7Y peptide which provides some of the affinity elements for tbe 
binding of PAI-1. 
PAI-1; Peptides: Plasmin; Vitronectin 
1. INTRODUCTION 
The activation of plasminoge~ by its natural activa- 
tors (e.g. tPA) provides a multipurpose biological tool 
for the proteolytic dissolution of barriers by plasmin. 
This activation has been reported to play an important 
role not only in fibrinolysis but also in inflammation, 
ovulation, tissue remodeling and development, angio- 
genesis, nerve regeneration, malignancy and tumor cell 
invasion [l-4]. In view of this diversity of functions it 
is obvious that plasmin activity must be under a strict 
regulatory control to secure a localized, site-restricted 
action and to limit its duration. 
In order to stop plasmin action it is not sufficient only 
to inactivate the excess of already-formed plasmin (by 
a,-antiplasmin [5]). It is also necessary to arrest further 
production of plasmin from plasminogen. This is 
achieved through the inhibition of plasminogen activa- 
tor(s) by PAI-I, which was shown to be bound to vitro- 
nectin [6,7] and thus to become stabilized in its active 
form both in circulating blood and in the ECM [8--l 11. 
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Using the specific phosphoryiation of vitronectin at 
$FR by platelet-released PKA 112-161, we recently 
showed [17] that plasmin specifically cleaves vitronectin 
at the R36’-S’6’ bond. 18 amino acids upstream from the 
site of the endogenous cleavage which gives rise to the 
two-chain form (V65+10) of this protein. We also re- 
ported that as a result of the plasmin cleavage, the 
affinity between vitronectin and PAI-I is si~i~~antly 
reduced 1171 and that this cleavage is stimulated by 
glycosaminoglycans which anchor vitronectin to the 
ECM, thus favouring the cleavage of the vitronectin 
molecules found in this matrix. On the basis of these 
findings, we proposed a mechanism through which plas- 
min can arrest its own production by feedback signaling 
(Scheme I in [17]). At the initial stage of fibrinolysis, the 
plasminogen activator converts plasminogen to plas- 
min. This is made possible since PAI-1 is then anchored 
(trapped) by the vitronectin molecules (which were pre- 
viously shown to be immobilized in the ECM [18], pre- 
sumably through glycosaminoglycans). This anchoring 
of PAI- locally depletes the inhibitor by preventing it 
from reaching and inhibiting the plasminogen activator. 
When plasmin levels become too high, the excess plas- 
min can clip preferentially the vitronectin molecules im- 
mobilized in the SubendotheIium. Consequently, the 
equilibrium between anchored PAI- and the detached 
(mobile) PAI- 1 is displaced, thus unleashing PAI- to 
reach and inhibit the plasminogen activator and arrest 
plasmin production. This unleashing actually represents 
a translocation, a transfer of the anchored PAI- from 
the ECM-bound (plasmin-clipped) vitronectin to solu- 
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Peptides 
Table I 
Amino acid composition of key peptides in the BP series* 
A R N Q G H K F P s Y 
BP4 0.85 5.32 1.98 2.14 2.0 0.98 _ 
(1) (6) (2) (2) (2) (1) _ 
BP4-1 _ 2.95 1.06 2.0 1.12 
_ (3) _ (1) (2) (1) 
BP5 4.1 _ 1.10 3.0 1.02 0.86 
(4) _ (1) (3) (1) (1) 
5.0 1.02 2.18 1.0 0.97 3.38 
(5) (1) (2) (1) (1) (3) 
_ 1.0 2.4 
(1) (4) 
_ 1.32 
(2) 
_ 1.56 1.05 
_ (2) (1) 
0.90 _ 0.81 1.10 
(1) _ (1) (1) 
*Values given are the number of nanomoles obtained in the analyis, while the values m brackets represent the integer numbers expected for the 
correct structure. 
ble vitronectin molecules which have not been clipped 
by plasmin and thus possess a higher affinity for PAI- 1. 
Since the nlasmin cleavage of vitronectin at the R’6’p 
S362 bond attenuates its P&-l binding, we assumed that 
the key PAI- binding elements could be located either 
at a distant site, the conformation of which is signifi- 
cantly affected by the integrity of the R36’S36’bond, or 
that these binding elements are located in the immediate 
vicinity of this bond. This paper shows that the latter 
is the case. 
2. MATERIALS AND METHODS 
2 1. Materials purchased 
Freshly frozen human plasma was obtained from the Tel-Hashomer 
Medical Center, Ramat-Gan, Israel. Rabbit anti-human vitronectin 
polyclonal antibodies were obtained from Calbiochem. B-Galactosi- 
dase-lmked Protein A and ortho-nitrophenyl-p-o-galactopyranoside 
(ONPG) were purchased from Amersham, UK. PAI- was obtained 
from American Diagnostica, New-York. All other chemicals were of 
the best available grade from commercial sources. 
2.2. i7~fronectw2 
Vitronectm was prepared from freshly frozen human plasma using 
Cycle number 
BP4 
Sequence determined 
Residue (yield’) 
Table II 
Sequence analysis of BP4. BP5 and BP6 
BP5 
Cycle number Sequence determined 
Residue (yield*) 
BP6 
Cycle number Sequence determined 
Residue (yield*) 
1 (58) 1 K 
2 (97) 2 G 
3 R 
4 G (Ii, 
3 Y 
4 R 
5 H (45) 5 
6 S (37) 6 : 
7 R ** 7 R 
8 G (34) 8 G 
9 R ** 9 H 
10 N (28) 10 S 
11 Q CO1 11 R 
12 N (15) 12 G 
13 S (15) 13 R 
14 R ** 
15 R ** 
16 P (25) 
17 S (9) 
18 R ** 
19 A (12) 
*Number of pmols of amino acid phenylthiohydantoin in derivative recovered. 
**Quahtatively identified (yield too low for quantitative determmation). 
(64) 1 
(47) 2 
(61) 3 
** 4 
(20) 5 
(44) 6 
** 7 
(26) 8 
(161 9 
(8) 10 
** 11 
(16) I2 
** 13 
14 
15 
16 
K (62) 
K (67) 
Q (68) 
R (13) 
F (69) 
R (19) 
H (14) 
R (22) 
N (52) 
R (24) 
K (40) 
G (34) 
Y (44) 
R (24) 
(13) 
(17) 
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VlI 
BP1 
BP2 
BP3 
BP4 
BP4-1 
BP4-2 
BP5 
BP6 
PAL1 BINDING SITE 
348 370 
I 
plasmin PKA 
) 
Endogenous 
cleavage phosph. cleavage 
348 1 378 c 382 
KKQRFRHRNRKGYRSQRGHSRGRNQNSRRPSRATW 
371 A 380 
NQ NSRRPSRA 
369 3eu 
GRNQ NSRRPSRA 
365 380 
GHSRGRNQ NSRRPSRA 
362 380 
SQRGHSRGRNQ NSRRPSRA 
362 370 
SQRGHSRGR 
362 368 
SQRGHSR 
353 370 
KGYRSQRGHSRGR 
348 X3 
KKQRFRHRNRKGYRSQ 
a purification procedure described elsewhere [15]. Our preparations 
usually contained the two molecular forms of this protein: V,,, a 
one-chain (75 kDa) form; and V,,,,,, a proteolytically clipped, two- 
chain protein (65 kDa and 10 kDa) held together by a disulfide bridge 
[19,20]. 
2.3. Pepride synthesu 
The synthesis of peptides was carried out manually, in a mechanical 
shaker, using the solid phase methodolo~ 1211, on a chloromethylated 
polystyrene - 1% dtvinylbenzene resin. a-Amino groups were pro- 
tected by the t-butyloxycarbonyl group. Side chain groups were 
masked by the following protectmg groups: S. by benzyl; Y, by 2.6- 
dichlorobenzyl; K, by 2-chlorobenzyloxycarbonyl: H, by ben- 
zyloxycarbonyl; and R, byp-toluene sulfonyl. The synthesis was miti- 
ated by coupling the C-terminal ammo acid to the resin. Peptide 
elongation (coupling) was performed with a 3-fold molar excess of the 
protected amino acid and an equimolar mixture of N,N-dicyclo- 
hexylcarbodiimide and I-hydroxybenzotriazole. Deprotection and de- 
tachment of the peptides from the polymeric carrier was carried out 
with anhydrous HF. The crude peptides were purified to homogeneity 
by preparative HPLC (Lichrosorb RP-8, Merck) using a linear gradi- 
ent between 0.1% trifluoroacetic acid in water and 0.1% of this acid 
in 75% a~tonit~ie/water. The structure of each of the peptides was 
confirmed by amino actd composition and sequence. The analyses of 
key peptides are given in Tables I and II. 
2.4. Procedures carried our as described in the hterature 
Protein concentration was determined by the method of Bradford 
1221. The binding of vitron~tin to immobilize PAI- was conducted 
as described by Salonen et al. [9]. The activation of PAI- by sodium 
dodecylsulfate was carried out as described by Katagiri et al. [23]. 
Amino acid sequencing was performed with an Apphed Biosystem 
415A sequencer. 
3. RESULTS AND DISCUSSION 
In order to map the PAI- binding site in vitronectin, 
we synthesized a series of peptides, the structure of 
which was derived from the amino acid sequence sur- 
rounding its plasmin cleavage site (R36’-S362) [17]. Each 
of these synthetic peptides (Scheme I) was tested by a 
competition ELISA assay for its ability to inhibit the 
binding of vitronectin to immoblized activated PAI-1. 
The first screening (Fig. 1) was carried out with an 
identical molar concentration (25 PM) of the peptides. 
In view of a possible variability in such tests (mainly due 
to some variability in the activated PAI- coating of the 
plates), a control of vitronectin alone was run alongside 
in each plate for reference. 
As seen in Fig. 1, all of the peptides BPI, BP2, BP3 
and BP4 (panels A and B) which cover the vitronectin 
sequence between the plasmin cleavage site (R36’-S362) 
and the endogenous cleavage site (R37g-A380) inhibit to 
some extent the binding of vitronectin to PAI-1. This 
inhibition is mainly due to the N-terminus moiety of 
BP4, since BP4-1 (S362-R370) was a rather effective in- 
hibitor (Fig. 1, panel C) while BP1 (N371-A380) exhibited 
a very minor inhibition, if any (Fig. 1, panel A). It 
should be noted that BP42 (S3a2-R368) which is only 
two amino acids shorter than BP4-1, was a less effective 
inhibitor (Fig. 1, panel C) suggesting that G369 and/or 
R3” may contain an important biorecognition element. 
Furthermore, the inhibition capacity of the various pep- 
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Fig. I. Effect of synthetic peptides from the BP serves on the binding 
of vitronectin onto immobilized PAI-I. The various synthettc pepttdes 
(all 50 PM) were dissolved in 50 ,u1 of a buffer composed of PBS, Tween 
20 (O.Ol%), polyethylene-glycol (average M.W. 8 kDa) (4% W/v). 
Their concentration was 50 ,uM m all cases. Each of the samples was 
added to a microtiter well coated wtth SDS-activated PAL1 prepared 
as described in the literature [23]. After an Incubation of 30 min at 
22°C. ahquots (50 pl) of a vitronectin solution (at varrous concen- 
trations) in the same buffer were added to each well. This was followed 
by an incubation for 2 h at 37°C. The amount of bound vitronectin 
was determined with specific rabbrt-anti-human Vn antibodies (1: 1000 
dtlution), followed by a j&galactosidase hnked protem A and using 
ONPG as a substrate. The enzymatic reaction was allowed to proceed 
for 60 min (22°C) and was stopped by the addrtion of 50 ,uI of 1 M 
Na,CO,, and the absorbance at 405+490 nm was measured. Each 
point in the graph represents the mean of trtplicate determinations. 
The final peptrde concentrations in the incubation mtxtures are 25,~M. 
tides could not be attributed merely to their positive 
charge, since BP41 (net charge +4) was found to be 
more effective than BP3 (net charge +6) or BP4 (net 
charge +7) (Fig. I, panels B and C). 
The peptide BP5 (K358-R370), which contains all of 
BP41 and a further extension beyond the plasmin 
cleavage site, was found to be more effective than BP41 
as an inhibitor (Fig. 1, Panel D). Furthermore, the pep- 
tide BP6 (K348-Q3”3) seemed to be the most effective in 
this series (Fig. 1, Panel D). 
In view of these results, we assessed the relative inhib- 
itory power of the peptides by measuring the concentra- 
tion dependence of the inhibition. As seen in Fig. 2, all 
three of the peptides BP4, BP5 and BP6 achieved a 
0.4 
0.2 
0.0 
.Ol .l 1 10 100 
B 
* +2.5uM BPS 
* +lOuMBPS 
- +25uMBPS 
- +25OuM BPS 
.Ol .I 1 10 
0.8 
* No additions 
e +2 5 uM BP6 
0.6 
* +SuMBP6 
_.- 
.Ol 
Vitrinectln, bglrnl 
10 
Fig. 2. Effect of the concentration of BP4 (panel A), BP5 (panel B) and 
BP6 (panel C) on the binding ofvitronectin to tmmobilized PAI-I. The 
experiments were carrred out as descrrbed in the legend to Fig. 1 with 
the Indicated final concentrattons of the pepttdes and of vitronectm. 
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o.oo+ --:; * . . . . ..*I * . . . ..*I . ..*.- 
1 10 100 
Peptide, pM 
Fig. 3. Comparing the efficacy of BP4, BP5 and BP6 in impeding the 
association of vitronectin to PAI-1. The titration was carried out as 
described in the legend to Fig. 1, except for the fact that the final 
concentration of vitronectin was constant (0.5 &ml), while the con- 
centration of the peptides was varied as indicated. 
maximal inhibition with increasing concentration. 
However, while BP4 did so at a concentration of 25 PM 
(Fig. 2, panel A), and BP5 at a concentration of 100 PM 
(Fig. 2, panel B), the peptide BP6 was maximally effec- 
tive already at a 2.5 ,uM concentration (Fig. 2, panel C). 
This is further illustrated in Fig. 3, where the relative 
inhibitory efficacy of these peptides is compared at one 
concentration of vitronectin (0.5 &ml) and with in- 
creasing peptide concentrations. It is apparent from this 
figure that all three peptides achieve the same level of 
inhibition (-65%). However, BP6 achieves this level of 
inhibition at a concentration which is 200- to 500-fold 
lower than BP4 and BP5. 
The results presented above indicate that while some 
high affinity elements of the PAI- binding site reside 
within the K348-R357 region, the complete PAI- binding 
site encompasses the K 34*-R37o sequence. This position- 
ing of the PAI- binding site can account for our previ- 
ous finding [17]** that upon cleavage of the R36’-S362 
bond by plasmin, the affinity between vitronectin and 
PAI- is attenuated to unleash the inhibitor, since the 
PAI- binding site is split in two by this cleavage. Fur- 
thermore, in the case of the two-chain (endogenously 
clipped) form of vitronectin, the plasmin cleavage de- 
taches the S362-R379 peptide, between the plasmin cleav- 
**While this manuscript was being prepared for publication, this find- 
ing was confirmed by Kost et al. [24] who also assigned the PAI- 
binding site within the sequence 348-370 in vitronectin, without re- 
porting the relative contribution of the various biorecognition ele- 
ments to the binding. 
age site and the endogenous cleavage site, which pro- 
vides some of the affinity elements for the binding of 
PAI- 1. 
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